

ORAL ONCOLOGY

PATIENT INFORMATION

| | | | | |
|-----------------------------|-------|-------------------------------|---------|---------------------|
| Name: | | SSN: | DOB: | |
| Address: | | City: | State: | ZIP: |
| Home Phone: | Cell: | Height: | Weight: | Gender: Female Male |
| Email: | | Allergies: | | |
| Primary Diagnosis (ICD-10): | | Secondary Diagnosis (ICD-10): | | |

INSURANCE INFORMATION (or attach copy of cards)

| | | | | |
|-----------------------|----------------|---------------|-----------|----------|
| Primary Insurance Co: | Policy Holder: | Relationship: | Policy #: | Group #: |
|-----------------------|----------------|---------------|-----------|----------|

PRESCRIPTION INFORMATION (or attach a copy of prescription)

| MEDICATION | STRENGTH | DIRECTIONS | QTY | REFILLS |
|--|--|--|-----|---------|
| REVLIMID® (lenalidomide)[†] <i>Complete lab section below</i> | <input type="checkbox"/> 2.5 mg <input type="checkbox"/> 5 mg <input type="checkbox"/> 10 mg <input type="checkbox"/> 15 mg <input type="checkbox"/> 20 mg <input type="checkbox"/> 25 mg | <input type="checkbox"/> Take _____ caps PO once a day on days 1-21, of a 28 day cycle <input type="checkbox"/> Take _____ caps PO once a day on days 1-14, of a 21 day cycle <input type="checkbox"/> Take _____ caps PO once a day on days 1-14, of a 28 day cycle <input type="checkbox"/> Take _____ caps PO once a day continuously on days 1-28 | | None |
| THALOMID® (thalidomide) | <input type="checkbox"/> 50 mg <input type="checkbox"/> 100 mg <input type="checkbox"/> 150 mg <input type="checkbox"/> 200 mg | <input type="checkbox"/> Take _____ caps PO once daily at bedtime | | None |
| POMALYST® (pomalidomide) | <input type="checkbox"/> 1 mg <input type="checkbox"/> 2 mg <input type="checkbox"/> 3 mg <input type="checkbox"/> 4 mg | <input type="checkbox"/> Take _____ caps PO once daily on days 1-21, of a 28 day cycle | | None |

Patient Type: Adult Female, Not of Reproductive Potential Adult Female, Reproductive Potential Female Child, Not of Reproductive Potential
 Female Child, Reproductive Potential Adult Male Male Child

Celgene Auth #: _____ **Date Issued:** _____

† To prevent delays and minimize phone calls please provide the following labs: **Serum Creatinine:** _____ **eGFR/CrCL:** _____ **Date:** _____

| | | | | |
|--|--|---|--|--|
| SPRYCEL® (dasatinib)[†] | <input type="checkbox"/> 20 mg <input type="checkbox"/> 50 mg <input type="checkbox"/> 70 mg <input type="checkbox"/> 80 mg <input type="checkbox"/> 100 mg <input type="checkbox"/> 140 mg | <input type="checkbox"/> Take _____ mg PO once daily with or without a light meal | | |
| GLEEVEC® (imatinib)[†] | <input type="checkbox"/> 100 mg <input type="checkbox"/> 400 mg | <input type="checkbox"/> Take _____ mg PO once daily without food | | |
| XELODA® (capecitabine)[†] <i>Complete lab section above</i> | <input type="checkbox"/> 150 mg <input type="checkbox"/> 500 mg Total dose: _____ mg | <input type="checkbox"/> Take total dose PO twice daily on days 1-14 of 21 day cycle. Repeat. <input type="checkbox"/> Take total dose PO twice daily in conjunction with radiation: <input type="checkbox"/> M-F <input type="checkbox"/> 7 days/week Radiation length of therapy: _____ <input type="checkbox"/> Other _____ | | |
| TEMODAR® (temozolomide)[*] | Total dose: _____ mg tablet | <input type="checkbox"/> Take _____ mg PO once daily for 5 days every 28 days <input type="checkbox"/> Take _____ mg PO once daily in conjunction with radiation for _____ days <input type="checkbox"/> Start Date _____ for _____ # of days a week <input type="checkbox"/> Other _____ | | |
| JADENU™ (deferasirox)[*] † <input type="checkbox"/> Tablets <input type="checkbox"/> Sprinkle Granules | <input type="checkbox"/> 90 mg <input type="checkbox"/> 180 mg <input type="checkbox"/> 360 mg | <input type="checkbox"/> Take _____ mg PO once daily with or without a light meal | | |
| EXJADE® (deferasirox)[*] † Tablets for Suspension | <input type="checkbox"/> 125 mg <input type="checkbox"/> 250 mg <input type="checkbox"/> 500 mg | <input type="checkbox"/> Take _____ mg PO once daily on an empty stomach at least 30 minutes before food | | |
| ZYTIGA® (abiraterone acetate)[*] | <input type="checkbox"/> 250 mg <input type="checkbox"/> 500 mg | <input type="checkbox"/> Take _____ mg PO once daily | | |
| with PREDNISONE <input type="checkbox"/> Rx sent to local pharmacy | _____ mg | <input type="checkbox"/> CRPC: Take 5 mg PO twice daily with food <input type="checkbox"/> CSPC: Take 5 mg PO once daily with food | | |

| | | | | | |
|---|--|---|--|---|--|
| AFINITOR® (everolimus)[*] | COTELLIC® (cobimetinib) | GAVRETO® (pralsetinib) | MEKTOVI® (binimetinib) | SORAFENIB™ | TYKERB® (lapatinib)[*] |
| AGRYLIN® (anagrelide)[*] | CYTOXAN® (cyclophosphamide)[*] | IBRANCE® (palbociclib) | MYLOTARG™ (gemtuzumab ozogamicin) | SUTENT® (sunitinib malate)[*] | VIZIMPRO® (dacomitinib) |
| ALECENSA® (alectinib) | DAURISMO™ (glasdegib) | IDHIFA® (enasidenib) | NILANDRON® (nilutamide) | TABRECTA® (capmatinib) | VOTRIENT® (pazopanib) |
| AUGTYRO™ (repotrectinib) | DEFERIPRONE™ | INLYTA® (axitinib) | ODOMZO® (sonidegib) | TAFINLAR® (dabrafenib) | XALKORI® (crizotinib)[†] |
| BESPONSA® (inotuzumab ozogamicin) | ERIVEDGE™ (vismodegib) | ITOVEBI™ (inavolisib) | ONUREG® (azacitidine) | TALZENNA® (talazoparib) | XTANDI® (enzalutamide) |
| BOSULIF® (bosutinib)[†] | ERLEADA™ (apalutamide) | KISQALI® (ribociclib) | PIQRAY® (alpelisib) | TARCEVA® (erlotinib)[*] | YONSA® (abiraterone acetate) |
| BRAFTOVI® (encorafenib) | FASLODEX® (fulvestrant)[*] | LENVIMA® (lenvatinib) | PROMACTA® (eltrombopag) | TARGRETIN® (bexarotene)[*] | ZELBORAF® (vemurafenib) |
| CABOMETYX® (cabozantinib) | FEMARA® (letrozole)[*] | LORBRENA® (lorlatinib)[†] | ROZLYTREK® (entrectinib) | TASIGNA® (nilotinib) | ZOLINZA™ (vorinostat) |
| COMETRIQ™ (cabozantinib) | FORTEO® (teriparatide) | MEKINIST™ (trametinib) | RYDAPT® (midostaurin) | | <small>*AVAILABLE IN GENERIC</small> |

Drug Name (write in one of the above): _____
 Dose: _____ Frequency: _____ Quantity: _____ Refills: _____

Drug Name (write in one of the above): _____
 Dose: _____ Frequency: _____ Quantity: _____ Refills: _____

Start of Therapy Date: _____ **Ship To:** Patient MD Office

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution. Dispense as written

PHYSICIAN INFORMATION

| | | |
|-----------------------|-----------|---------------|
| Prescriber Name: | Phone: | Fax: |
| Office Contact: | Email: | |
| Address: | City: | State: ZIP: |
| NPI #: | Tax ID #: | |
| Prescriber Signature: | Date: | |